Clinical Trial Update: Genomics Study in CML Patients With Ponatinib Treatment

View source ↗

Summary

A genomics-focused study evaluating ponatinib in patients with chronic myeloid leukemia (BCR-ABL1 positive) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: Dong-Wook Kim | Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Status: COMPLETED